Systemic Lupus Erythematosus (SLE)

Populations and Risk Factors

• Women affected approximately 9:1 to 15:1 over men; onset most common during childbearing years (15–45), though can occur at any age
• Black, Hispanic, and Asian populations affected 2–3 times more frequently than Caucasians, with tendency toward more severe disease
• Strong genetic component: concordance rate in identical twins is 25–50%; first-degree relatives have a 5–8% risk; HLA-DR2 and HLA-DR3 alleles associated with susceptibility
• Hormonal influence: estrogen promotes B-cell autoreactivity and antibody production — explains female predominance, worsening during pregnancy and oral contraceptive use, and improvement post-menopause
• UV light exposure is the most common environmental trigger — directly damages DNA, releasing nuclear antigens that feed the autoimmune cycle
• Drug-induced lupus: hydralazine, procainamide, isoniazid, and certain biologics can trigger a lupus-like syndrome that resolves when the drug is discontinued
• Viral triggers hypothesized: Epstein-Barr virus molecular mimicry may initiate autoantibody production in genetically susceptible individuals
• Smoking increases risk approximately 1.5 times and accelerates renal involvement

Causes and Pathophysiology

Immune Complex Mechanism

• Initiating event: In genetically predisposed individuals, environmental triggers (UV light, viral infection, hormonal shifts) cause accelerated apoptosis and impaired clearance of apoptotic cell debris. Nuclear self-antigens (DNA, histones, ribonucleoproteins) that are normally hidden inside cells become exposed to the immune system.
• Autoantibody production: Autoreactive B-cells — normally deleted or silenced — escape tolerance checkpoints and produce pathogenic autoantibodies: antinuclear antibodies (ANA, present in >95% of SLE patients), anti-double-stranded DNA (anti-dsDNA, highly specific for SLE), anti-Smith (anti-Sm), and anti-phospholipid antibodies. These antibodies bind to circulating nuclear antigens, forming immune complexes.
• Immune complex deposition: These antigen-antibody complexes circulate in the blood and deposit along the walls of blood vessels, in the glomerular basement membrane of the kidneys, in the synovium of joints, and on serosal surfaces (pleura, pericardium). Deposition activates the complement cascade (C3, C4), recruiting neutrophils and macrophages that release inflammatory mediators — producing the widespread, multisystem tissue damage characteristic of SLE.
• Why "The Great Imitator": Because immune complexes deposit wherever blood vessels supply tissue, virtually any organ system can be affected — skin, joints, kidneys, brain, heart, lungs, blood vessels, serosal membranes. This protean presentation mimics RA, MS, fibromyalgia, vasculitis, and many other conditions.

Musculoskeletal Involvement

• Arthralgia and arthritis (90%+ of patients): SLE causes synovial inflammation similar to RA but critically without the pannus formation and erosive destruction — the synovitis is driven by immune complex deposition rather than invasive granulation tissue. This means joints are painful and swollen during flares but do not develop the irreversible cartilage and bone erosion seen in RA.
• Jaccoud arthropathy: In approximately 5–10% of chronic SLE patients, repeated episodes of synovitis and tenosynovitis produce ligamentous laxity and tendon displacement around the MCP joints, causing reducible deformities (ulnar deviation, swan-neck) that mimic RA deformities. The critical distinction: Jaccoud deformities are passively correctable because the joint surfaces are intact — RA deformities are fixed because the joint is structurally destroyed. This directly affects palpation findings and mobilization decisions.
• Avascular necrosis (AVN): Immune complex deposition in small blood vessels combined with long-term corticosteroid use (which disrupts intraosseous blood supply) causes ischemic necrosis of bone, most commonly affecting the femoral head and humeral head. AVN occurs in 10–15% of SLE patients and produces deep, progressive joint pain that worsens with weight-bearing — distinct from the shifting, inflammatory joint pain of active SLE.
• Myalgia and muscle weakness: Generalized myalgia affects 50–80% of patients during flares from inflammatory myopathy (immune complex deposition in muscle microvasculature) and deconditioning from prolonged fatigue-related inactivity. True inflammatory myositis (elevated CK, proximal weakness) occurs in approximately 5–10%.

Vascular and Systemic Manifestations

• Raynaud phenomenon (30–40%): Vasospasm of digital arteries from immune-mediated endothelial injury and autonomic dysregulation. This is secondary Raynaud — more severe than primary, with potential for digital ulceration. It creates cold, poorly perfused digits that must be assessed before distal hand work.
• Lupus nephritis: Immune complex deposition in the glomerular basement membrane triggers inflammation and fibrosis — the most serious visceral complication and the most common cause of death in SLE. Signs include peripheral edema (legs, periorbital), hypertension, and proteinuria. Edema affects treatment positioning and contraindicates aggressive lymphatic drainage toward already-compromised kidneys.
• Vasculitis: Immune complex deposition in blood vessel walls causes inflammation ranging from livedo reticularis (net-like purplish skin mottling) to digital gangrene in severe cases. Small and medium vessel vasculitis can affect peripheral nerves (mononeuritis multiplex), causing numbness and weakness that must be distinguished from compression neuropathy.
• Antiphospholipid syndrome (30–40%): Antiphospholipid antibodies promote hypercoagulability, creating a significantly elevated risk of deep vein thrombosis, pulmonary embolism, and stroke. This DVT risk is an active concern during massage therapy planning.
• Serositis: Immune complex deposition on serosal surfaces produces pleuritis (sharp chest pain on deep breathing) and pericarditis — the chest pain must be differentiated from cardiac ischemia.
• Neuropsychiatric lupus: Immune complex deposition and vasculitis in the central nervous system cause cognitive dysfunction ("lupus fog"), seizures, psychosis, and headaches in 25–70% of patients.

Flare and Remission Cycle

• Flare triggers: UV light exposure, infection, emotional stress, pregnancy, estrogen-containing medications, and medication non-compliance can all precipitate flares. The unpredictability of flares creates significant psychosocial stress.
• Flare assessment: Active systemic flare presents with fatigue, malaise, low-grade fever, new or worsening rash, increased joint pain, and elevated anti-dsDNA antibodies with low complement (C3, C4). Like RA, the flare/remission state directly determines the massage treatment approach — systemic flare contraindicates vigorous massage; remission permits full treatment with modifications.

Signs and Symptoms

Active Flare

• Malar (butterfly) rash: erythematous rash across the cheeks and bridge of the nose, sparing the nasolabial folds — present in approximately 50% of patients and exacerbated by UV exposure
• Shifting polyarthralgia or polyarthritis — affects multiple joints in a migratory pattern, typically the MCPs, PIPs, wrists, and knees bilaterally; swelling present but without the erosive destruction of RA
• Debilitating fatigue disproportionate to activity level — the most common and often most disabling symptom, present in 80–100% of patients
• Low-grade fever, malaise, weight loss, and generalized myalgia during flares
• Discoid rash: raised, scaly, coin-shaped lesions on sun-exposed skin that can cause scarring and permanent alopecia
• Photosensitivity: rashes triggered or worsened by UV exposure
• Painless oral or nasal ulcers (present in approximately 40%)
• Raynaud phenomenon: triphasic color change (white-blue-red) in digits triggered by cold or stress

Chronic / Between Flares

• Persistent fatigue and deconditioning from cumulative disease burden
• Jaccoud arthropathy: reducible MCP deformities (ulnar deviation, swan-neck) from chronic ligamentous laxity — worsens over time but remains passively correctable
• Avascular necrosis: deep, progressive joint pain (typically hip or shoulder) that worsens with weight-bearing; not related to flare activity
• Alopecia (diffuse or patchy) from follicular immune complex deposition
• Livedo reticularis: net-like purplish mottling of the skin indicating underlying vasculitis
• Peripheral edema indicating renal involvement (lupus nephritis)
• Compensatory postural changes from chronic pain, fatigue, and protective guarding

Systemic Features

• Pleuritis: sharp chest pain on deep breathing from pleural inflammation
• Pericarditis: chest pain worse when lying down, relieved by leaning forward
• Peripheral neuropathy: numbness, tingling, or weakness from vasculitis-induced nerve damage
• Cognitive dysfunction ("lupus fog"): difficulty with concentration, memory, and word-finding
• DVT risk from antiphospholipid syndrome — leg swelling, warmth, or calf pain requires screening

Assessment Profile

Subjective Presentation

• Chief complaint: "My joints ache all over — it moves around. My hands are stiff in the morning and I'm exhausted all the time." Patients often describe a combination of shifting joint pain, overwhelming fatigue, and skin rashes that worsen in sunlight. The joint pain is characteristically migratory — affecting different joints on different days.
• Pain quality: Deep, aching joint pain during flares — less intense than RA at its worst but more widespread and shifting; may describe a "body-wide soreness" similar to flu-like myalgia; hip or shoulder pain that is deep, constant, and worsening with weight-bearing may indicate AVN rather than active lupus
• Onset: Insidious, often over months to years with a relapsing-remitting pattern; flares triggered by UV exposure, stress, infection, or hormonal changes; many patients describe a long diagnostic journey before SLE is confirmed
• Aggravating factors: Sun exposure (worsens rash and triggers flares), cold (triggers Raynaud), emotional stress, infection, fatigue, overexertion, estrogen-containing medications
• Easing factors: Rest (but fatigue persists regardless), sun avoidance, warmth for Raynaud episodes, NSAIDs and hydroxychloroquine (Plaquenil) for joint symptoms, immunosuppressants during flares, stress management
• Red flags: New onset severe headache, seizures, or sudden cognitive change → neuropsychiatric lupus or CNS vasculitis; emergency referral; unilateral leg swelling, warmth, and calf pain → DVT screening required (antiphospholipid syndrome); progressive periorbital or pedal edema with hypertension → lupus nephritis; urgent medical evaluation; chest pain on deep breathing → differentiate pleuritis from cardiac event

Observation

• Local inspection: Malar butterfly rash across cheeks and nose (sparing nasolabial folds) — pathognomonic when present; discoid lesions on sun-exposed skin; alopecia (diffuse thinning or patchy); livedo reticularis on extremities; periorbital or pedal edema suggesting renal involvement; digital color changes (Raynaud); oral ulcers on inspection of lips and buccal mucosa; Jaccoud deformities of the MCP joints (reducible ulnar deviation or swan-neck) in chronic disease; thin, fragile skin from long-term corticosteroid use
• Posture: Forward head posture and rounded shoulders from chronic fatigue and protective guarding; compensatory cervical and thoracic tension patterns from general deconditioning; antalgic posture protecting affected joints; hip flexion or limping if AVN of the femoral head is present
• Gait: May be normal between flares; antalgic gait with shortened stride during joint flares; limping or Trendelenburg pattern if femoral head AVN has developed; cautious gait from generalized weakness and deconditioning

Palpation

• Tone: Generalized deconditioning produces diffuse muscle atrophy and reduced resting tone in chronic SLE; compensatory hypertonicity in upper trapezius, cervical extensors, and thoracolumbar paraspinals from chronic pain guarding and fatigue-related postural deterioration; proximal weakness patterns (hip flexors, shoulder girdle) from inflammatory myopathy during flares or cumulative deconditioning; bilateral patterns reflecting systemic disease
• Tenderness: Active joint tenderness is present during flares — synovial thickening produces a boggy, spongy quality similar to RA but typically milder; Jaccoud joints may be tender along tendon sheaths from chronic tenosynovitis; widespread myalgia during flares produces diffuse muscle tenderness (not localized to specific trigger points as in fibromyalgia); deep tenderness over the femoral head or humeral head with weight-bearing reproduction suggests AVN — distinct from inflammatory flare tenderness
• Temperature: Actively inflamed joints are mildly warm during flares — less dramatically hot than RA joints; digits may be cool or cold from Raynaud vasospasm; compare bilateral digital temperature as a baseline; livedo reticularis areas may feel cool from underlying vasculitis; skin over the malar rash may feel warm from active dermatitis
• Tissue quality: Skin may be thin and fragile from long-term corticosteroid use (easy bruising, tearing); subcutaneous edema in dependent areas (ankles, periorbital) from renal involvement; Jaccoud joints have palpable ligamentous laxity — deformities reduce with passive correction, unlike the fixed bony deformities of RA; generalized reduced muscle bulk from deconditioning; digital skin may show pitting or ulceration in severe secondary Raynaud

Motion Assessment

• AROM: Reduced during flares in affected joints — typically MCPs, PIPs, wrists, knees, and shoulders; Jaccoud arthropathy produces apparent ROM restriction that improves when the examiner passively corrects the deformity (because the joint surfaces are intact); morning stiffness is present but typically <30 minutes (shorter than RA); generalized weakness and fatigue limit active movement globally even when specific joints are not inflamed; AVN produces progressive loss of hip or shoulder ROM, particularly internal rotation of the hip
• PROM / end-feel: During flares: guarded or protective end-feel from pain; Jaccoud joints: end-feel is soft or springy (ligamentous laxity) rather than the firm/leathery end-feel of RA capsular fibrosis — deformities reduce with gentle passive correction; AVN joints: initially guarded, progressing to hard/bony end-feel as the femoral or humeral head collapses; PROM exceeds AROM during flares (pain limits active more than passive movement)
• Resisted testing: Generalized weakness from deconditioning and inflammatory myopathy during flares; pain on resisted testing of actively inflamed joints; grip strength reduced bilaterally; proximal muscle weakness (deltoid, hip flexors) if inflammatory myositis is active — distinguished from deconditioning by elevated CK levels; weakness is typically symmetrical

Special Test Cluster

Note: If the patient reports deep, progressive hip pain worsening with weight-bearing (disproportionate to flare activity), add Thomas test and hip internal rotation assessment to screen for avascular necrosis of the femoral head. If neurological symptoms are present (numbness, weakness, cognitive changes), add relevant neurological screen.

Differential Assessment